Semaglutide vs Retatrutide

Retatrutide is the new player here, and the framing this page is built around is maturity. Semaglutide has years of large-population real-world data behind it; retatrutide is in late-phase trials with a phase-2 readout that reported about 24 percent average weight loss at 48 weeks in the highest-dose arm — a number larger than anything semaglutide has produced. The trade is what you would expect from a not-yet-approved molecule: less long-term safety data, fewer published edge cases, and prescribing pathways that still depend on which clinic and which compounding pharmacy a reader is working with.

Mechanism is the structural difference. Semaglutide hits GLP-1 alone; retatrutide is a triple agonist covering GLP-1, GIP, and glucagon. The glucagon arm is the unusual one — adding glucagon agonism on top of GLP-1 and GIP is the bet that pushed the trial weight-loss numbers higher, and it is also the source of the most frequently asked question about the molecule in real-world logs (whether the glucagon arm changes liver-fat dynamics in either direction). That question is still being answered in the published literature.

Dosing cadence is identical at one subcutaneous shot per week, but every other variable in the schedule diverges. Semaglutide's 0.25 mg opening step exists to buy gut tolerance and produces almost no weight-loss signal in the first month. Retatrutide's published trial schedule begins at 2 mg and steps through 4, 8, and 12 mg arms, which means a reader logging the triple-agonist will see meaningful changes in unit count on a U-100 syringe at every titration event rather than a long flat opening. The mg-to-units converter linked below handles either molecule once vial concentration is set, but the unit ranges are not interchangeable across the two ladders.

For someone deciding which of the two to log over a six-month window, the practical question is mostly access and risk tolerance for a still-trial-stage molecule. Semaglutide's data set is mature; retatrutide's is promising but limited. The numbers in the side-by-side table are computed from the same example vial fields as every other comparison on the site, so the dose-per-vial and approximate vial-duration columns are directly comparable.

For the Semaglutide vs Retatrutide decision specifically, the calendar shape is what most readers underweight. Semaglutide's example vial is 5 mg drawn against 0.25 mg per dose at 1 dose per week. Retatrutide's example vial is 10 mg drawn against 2 mg per dose at 1 dose per week. Those four numbers feed every column in the table above; change any one and the semaglutide vs retatrutide comparison shifts with it.

Concentration in this pair: Semaglutide sits at 2.50 mg/mL on the example reconstitution; Retatrutide sits at 5.00 mg/mL on its example. That single ratio is what determines how many U-100 syringe units a given dose of either molecule actually draws, so it is the first thing to confirm before treating any "Semaglutide vs Retatrutide" unit number on the internet as authoritative.

Doses per vial in this matchup work out to roughly 20 for Semaglutide and 5 for Retatrutide at the example dose sizes, with vial-duration windows near 20.0 weeks and 5.0 weeks respectively. Refill cadence follows directly from those windows, which is why the semaglutide vs retatrutide pair shows up in planning conversations more than in pure mechanism conversations.

When readers compare Semaglutide against Retatrutide, the Semaglutide-side mistakes that show up most in logs are: Switching to a new vial of the same peptide and reusing the old unit count without re-running the calculation against the new vial's diluent volume. Storing reconstituted semaglutide at room temperature for hours before refrigerating, especially after a travel day. Dosing twice in the same week after forgetting whether the previous injection was Sunday or Monday — almost always a logging-gap problem, not a math problem. Reading 0.25 mg as 25 units on the syringe regardless of vial concentration. The unit count is not fixed — it depends on the diluent volume. Each of these gets amplified when a reader is also actively comparing against Retatrutide, because muscle memory from one molecule's unit math leaks into the other.

Semaglutide question worth answering up front — How is semaglutide reconstituted? By adding a measured volume of bacteriostatic water to the lyophilized vial through the rubber stopper, then swirling — not shaking — until the powder fully dissolves into a clear solution. The exact diluent volume is up to the user; common choices for a 5 mg vial are 1, 2, or 3 mL.

Semaglutide question worth answering up front — How many units of semaglutide are in 0.25 mg? It depends on the concentration of your vial. On a 5 mg vial reconstituted with 2 mL of bacteriostatic water, 0.25 mg is exactly 10 units on a U-100 insulin syringe. On a 5 mg vial reconstituted with 1 mL, the same dose is 5 units.

On the Retatrutide side of the Semaglutide vs Retatrutide decision, the recurring mistakes are: Reusing a unit count from a previous vial without re-checking the new vial's diluent volume. Confusing retatrutide doses with semaglutide or tirzepatide doses — the milligram ranges differ and the math does not transfer. Skipping the escalation date in the log, then losing the timeline of when each step actually occurred. Letting reconstituted retatrutide warm to room temperature for extended periods on travel days. These are not generic dosing slips — they are the ones that compound when Retatrutide is being logged in parallel with Semaglutide.

Retatrutide question worth answering up front — How is retatrutide reconstituted? By drawing a measured volume of bacteriostatic water into a syringe and injecting it slowly into the lyophilized vial through the rubber stopper, then swirling — not shaking — until the powder fully dissolves into a clear solution.

Retatrutide question worth answering up front — How many units of retatrutide are in 2 mg? It depends on the concentration of your vial. On a 10 mg vial reconstituted with 2 mL of bacteriostatic water (5 mg per mL), 2 mg is exactly 40 units on a U-100 syringe.